Parr Mcknight Wealth Management Group LLC acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,256 shares of the medical technology company's stock, valued at approximately $1,532,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Kohmann Bosshard Financial Services LLC bought a new position in Stryker during the 4th quarter worth approximately $25,000. Rakuten Securities Inc. raised its holdings in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker during the fourth quarter worth $30,000. BankPlus Trust Department acquired a new position in Stryker during the fourth quarter worth $33,000. Finally, VSM Wealth Advisory LLC acquired a new position in Stryker during the fourth quarter worth $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.
Insider Transactions at Stryker
In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.20% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
SYK has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Royal Bank of Canada lifted their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Finally, Stifel Nicolaus boosted their target price on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $427.30.
Check Out Our Latest Stock Report on Stryker
Stryker Price Performance
SYK stock traded up $0.40 during trading on Thursday, reaching $380.79. 276,699 shares of the company were exchanged, compared to its average volume of 1,340,360. The company has a 50-day moving average of $368.42 and a two-hundred day moving average of $376.23. The company has a market capitalization of $145.34 billion, a price-to-earnings ratio of 49.11, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the prior year, the company earned $2.50 EPS. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also

Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.